Quantcast

Latest Fixed dose combination Stories

2011-01-20 06:00:00

PITTSBURGH, Jan. 20, 2011 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Matrix Laboratories Limited has received tentative approval from the U.S. Food and Drug Administration (FDA) under the President's Emergency Plan for AIDS Relief (PEPFAR) for its New Drug Application (NDA) for Lamivudine and Zidovudine Tablets, 30 mg/60 mg. The NDA is based on the reference listed drug Combivir®, by ViiV Healthcare. This innovative pediatric fixed-dose...

2011-01-05 14:53:00

CHAPEL HILL, N.C., Jan. 5, 2011 /PRNewswire/ -- The pharmaceutical industry's steep patent cliff and relatively lackluster pipeline is pushing strategy and development executives to uncover opportunities for sustainable growth in 2011. One opportunity lies in combination therapies with branded products to extend patent life. For pharma companies, fixed dose combination (FDC) products can extend a therapeutic advantage and become part of lifecycle management. For the patient, FDC products...

2010-10-27 07:00:00

BURLINGTON, Mass., Oct. 27 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the HIV drug market will experience an average annual increase of 3.1 percent from 2009 to 2014 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan. Thereafter, market growth will slow to 2.2 percent annually from 2014 through 2019, owing largely to the generic erosion of several key...

2010-07-26 07:30:00

TITUSVILLE, N.J., July 26 /PRNewswire/ -- Tibotec Pharmaceuticals today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for TMC278 (rilpivirine), an investigational non-nucleoside reverse transcriptase inhibitor (NNRTI), being studied for once-daily use with other antiretroviral agents in treatment-naive HIV-1-infected adults. If approved, TMC278 will be the third anti-HIV compound to be introduced by Tibotec Pharmaceuticals. The...

2010-07-22 07:30:00

VIENNA, July 22 /PRNewswire/ -- Tibotec Pharmaceuticals announced today results from two pivotal Phase 3, double-blind, randomized clinical trials comparing the efficacy, safety and tolerability of its investigational non-nucleoside reverse transcriptase inhibitor (NNRTI) TMC278 (rilpivirine) versus efavirenz (EFV), each administered once daily with a nucleoside/nucleotide background regimen in treatment-naive, HIV-1-infected adults. These global trials, known as ECHO and THRIVE, reached...

2010-06-02 07:00:00

WALTHAM, Mass., June 2 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of HIV, Gilead and Tibotec (a wholly owned subsidiary of Johnson & Johnson) remain on track to launch three novel treatment options in the next two years - Gilead's Quad (a four drug, one pill, once-daily, regimen), Tibotec's rilpivirine and Gilead/Tibotec's rilpivirine/emtricitabine/tenofovir...

2010-04-28 10:47:00

ABBOTT PARK, Ill., April 28 /PRNewswire/ -- Abbott announced today that the U.S. Food and Drug Administration (FDA) approved once-daily dosing of Kaletra® (lopinavir/ritonavir) for adult patients with HIV who have previously taken antiretroviral therapy. Kaletra once-daily dosing is already indicated for adult patients new to antiretroviral treatment. This gives treatment-experienced patients who have HIV that responds to Kaletra another dosing option as determined by...

2010-01-07 07:00:00

WALTHAM, Mass., Jan. 7 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that a hypertension drug that requires less-frequent dosing than Novartis's Diovan/Tareg (valsartan) would earn 30 percent patient share according to surveyed U.S. cardiologists. Similarly, in Europe, such an agent would earn comparable patient share of 25 percent according to surveyed European cardiologists. These patient shares...

2010-01-04 08:28:00

WALTHAM, Mass., Jan. 4 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, in 2018, the fixed dose coformulation of Tibotec's* rilpivirine and Gilead's Truvada will achieve blockbuster sales of more than $2 billion in the HIV drug market in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. The Pharmacor finding from the topic entitled Human Immunodeficiency Virus...

2009-10-06 09:26:00

NEW YORK, Oct. 6 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Reportlinker Adds Gilead Sciences Inc.: PharmaVitae Profile http://www.reportlinker.com/p0151769/Reportlinker-Adds-Gilead-Sciences-Inc-PharmaVitae-Profile.html Introduction This analysis examines the historical and forecast performance for Gilead in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and...


Word of the Day
blee
  • Color; hue; complexion.
This word is Middle English in origin.
Related